Tonix Pharmaceuticals Holding Corp.
TNXP
Rank in Stocks
#20881
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily... Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Share Price
$4.49
Last synced: 2026-11-09
Market Cap
$77.01M
Change (1 day)
-5.27%
Change (1 year)
-74.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tonix Pharmaceuticals Holding Corp. (TNXP)
Category
Healthcare
EPS for Tonix Pharmaceuticals Holding Corp. (TNXP)
EPS as of June 2026 TTM: $-13.24
According to Tonix Pharmaceuticals Holding Corp.'s latest financial reports, its current EPS (TTM) is $-13.24. At the end of 2025 the company had an EPS of $-14.57, an increase over its 2024 EPS of $-176.60.
EPS history for Tonix Pharmaceuticals Holding Corp. from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-13.24 | -9.13% |
| 2025 | $-14.57 | -91.75% |
| 2024 | $-176.60 | -97.23% |
| 2023 | $-6.37K | 684.65% |
| 2022 | $-811.68 | -99.50% |
| 2021 | $-163.97K | 3,143.04% |
| 2020 | $-5.06K | 30.78% |
| 2019 | $-3.87K | -78.60% |
| 2018 | $-18.06K | -66.56% |
| 2017 | $-54.02K | -72.88% |
| 2016 | $-199.19K | -61.04% |
| 2015 | $-511.21K | -0.04% |
| 2014 | $-511.41K | 36.26% |
| 2013 | $-375.31K | -60.28% |
| 2012 | $-945.00K | 63.40% |
| 2011 | $-578.35K | -70.56% |
| 2010 | $-1.96M | 6,264.30% |
| 2009 | $-30.87K | 46.05% |
| 2008 | $-21.13K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -218.28% |
US
|
|
| $-7.07 | -46.60% |
US
|
|
| $-5.29 | -60.05% |
AU
|
|
| $12.88 | -197.28% |
BE
|
|
| $21.56 | -262.84% |
NL
|
Questions about Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS)
What is Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS)?
Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS) over the last twelve months is $-13.24, as of Jun 2026.
What was Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS) in 2025?
In 2025, Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS) was $-14.57, compared with $-176.60 in 2024.
How has Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS) was highest in 2025 ($-14.57) and lowest in 2021 ($-163.97K).
How does Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS) compare with similar companies?
Tonix Pharmaceuticals Holding Corp.'s earnings per share (EPS) ($-13.24) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.